DECODE: Knowledge, Attitude, and Practices of Indian Dermatologists on the Scope of Tofacitinib in Dermatological Disorders

Background: Given the evolving treatment landscape in clinical dermatology, understanding the efficacy, safety, and optimal use of tofacitinib for dermatological disorders is crucial. The present survey evaluated knowledge, attitude, and practices regarding tofacitinib usage in various dermatological disorders among Indian dermatologists. Methods: A cross-sectional, observational, digital questionnaire-based nationwide survey was conducted among dermatologists. The questionnaire included 24 questions to gauge the scope of tofacitinib in the management of various dermatological conditions. Results: A total of 52 dermatologists completed the survey. Alopecia areata (AA), vitiligo, and psoriasis are challenging conditions seen frequently in the Indian dermatology clinics associated with significant psychosocial and financial burden and poor quality of life. Survey results indicated that oral tofacitinib was preferred as the first choice of therapy by dermatologists in severe AA (52%) and generalized vitiligo (31%). Tofacitinib is less commonly used for treating psoriasis, and 51% dermatologists have used tofacitinib in only ≤5% of their moderate-to-severe psoriasis patients. Clinical experience with tofacitinib was rated “good” by >65% of dermatologists. 31% of dermatologists perceived gastrointestinal disturbances as the most common side effect of tofacitinib, while 96% perceived no serious adverse events. There was an agreement among all the dermatologists who participated in the survey that oral tofacitinib treatment reduces oral steroid usage in AA and vitiligo patients. Conclusion: This survey highlights the role of tofacitinib in dermatology within the Indian context, providing real-world insights regarding treatment patterns of tofacitinib in dermatological disorders such as AA, vitiligo, and psoriasis.